Clinical trial

MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis

NCT04680962

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2023-08-03

PhasePHASE3

Study timeline

Study start (actual)2023-08-03Date precision: day

Registry last updated2023-08-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Rheumatoid Arthritisunresolved

Interventions

MabionCD20 (candidate biosimilar to rituximab)BIOLOGICAL

MabThera®BIOLOGICAL

Rituxan®BIOLOGICAL

Sponsors & collaborators

Mabion SAlead sponsor

Parexelcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04680962 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.